| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SCN3B |
| Uniprot No | Q9NY72 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 23-159aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MGSFPVCVEV PSETEAVQGN PMKLRCISCM KREEVEATTV VEWFYRPEGG KDFLIYEYRN GHQEVESPFQ GRLQWNGSKD LQDVSITVLN VTLNDSGLYT CNVSREFEFE AHRPFVKTTR LIPLRVTEEA GEDFTSVVSE |
| 预测分子量 | 18 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下为基于SCN3B重组蛋白研究的示例性参考文献(建议通过学术数据库验证具体信息)：
1. **文献名称**: *Functional Characterization of SCN3B Mutations in Long QT Syndrome*
**作者**: Valdivia CR, et al.
**摘要**: 研究通过重组蛋白技术表达SCN3B突变体，发现其影响心脏钠通道失活功能，可能导致长QT综合征的致病机制。
2. **文献名称**: *SCN3B Modulates Nav1.5 Channel Subcellular Localization in Cardiomyocytes*
**作者**: Yanagi K, et al.
**摘要**: 利用重组SCN3B蛋白进行体外实验，揭示其通过调控Nav1.5通道的膜定位影响心肌细胞动作电位传导。
3. **文献名称**: *Structural Insights into SCN3B Interaction with Voltage-Gated Sodium Channels*
**作者**: Olesen MS, et al.
**摘要**: 通过重组蛋白结晶和结构分析，阐明SCN3B与Nav通道的β亚基结合模式及其对通道门控的调控作用。
4. **文献名称**: *SCN3B Expression in Neuronal Cells Alters Sodium Current Density*
**作者**: Hu D, et al.
**摘要**: 在神经元模型中过表达重组SCN3B蛋白，发现其通过调节钠电流密度影响神经元兴奋性，提示其在神经系统疾病中的潜在作用。
---
提示：以上为模拟示例，建议通过 **PubMed/Google Scholar** 以关键词 "SCN3B recombinant protein" 或结合具体研究领域(如心脏、神经)检索最新文献。
**Background of SCN3B Recombinant Protein**
The SCN3B gene encodes the β3 subunit of voltage-gated sodium (Nav) channels, which are critical for initiating and propagating action potentials in excitable cells. As an auxiliary subunit, β3 modulates channel gating, trafficking, and cell adhesion, influencing electrical signaling in the heart and nervous system. SCN3B is particularly associated with Nav1.5 (SCN5A), the primary cardiac sodium channel, and its dysfunction has been linked to arrhythmias (e.g., Brugada syndrome) and neurological disorders.
Recombinant SCN3B protein is produced using biotechnological methods, such as expression in *E. coli* or mammalian cell systems, followed by purification. This engineered protein retains the functional extracellular immunoglobulin domain of β3. which mediates interactions with Nav α-subunits and cell adhesion molecules. Researchers utilize SCN3B recombinant protein to study sodium channel regulation, investigate disease mechanisms, and screen potential therapeutics targeting channelopathies.
In cancer biology, SCN3B has emerged as a tumor suppressor in certain contexts, with reduced expression observed in malignancies like lung adenocarcinoma. Recombinant SCN3B aids in exploring its role in metastasis and electrical signaling dysregulation in tumors. Additionally, it serves as an antigen for antibody development and a tool for structural studies to resolve interaction interfaces with partner proteins.
Overall, SCN3B recombinant protein provides a versatile platform for dissecting sodium channel biology, understanding pathophysiology, and advancing diagnostic or therapeutic strategies for cardiac, neurological, and oncological disorders.
×
